ESR1 and breast carcinoma: The identical FOXA1 promoter mutation is reported to be a hotspot mutation in breast cancer, albeit mutated in <1% of patients, and is known to upregulate the transcription of this gene and to give a growth advantage to breast cancer cells under anti-estrogen receptor therapy in vitro.